Vertidiag's scientific platform

Vertidiag has a unique scientific platform, combining vivo (rodent models of peripheral vestibulopathies) and vitro (organotypic cultures of vestibular sensory epithelia and Scarpa lymph nodes) models with functional and histological approaches. This double expertise enables both the search for evidence of effect (PoC) of pharmacological compounds active on vertiginous syndrome, and the identification of sites of action and mechanisms of action (MoA).

These study methods and models come from Vertidiag’s founding academic team. These approaches have led to the discovery of several biological mechanisms involved in peripheral vestibulopathies, some of which contribute to the endogenous compensation process.

This is the case, for example, of the overexpression of the SK potassium channels (Tighilet et al. 2019) and the phenomenon of reactive neurogenesis (Tighilet and Chabbert 2019) which occur at the level of deafferented vestibular nuclei, or the process of spontaneous synaptic repair (Cassel et al. 2019) which occurs within damaged vestibular organs of the inner ear.

This knowledge is a key asset in developing effective and derisive drug candidates with targeted mechanisms of effect and no side effects. Vertidiag’s priority today is to reposition molecules already on the market in order to reduce development times and shorten development times.